Atorvastatin acid

CAS: 134523-00-5

Ref. 3D-FF59474

Información del producto

• Nombre: Atorvastatin acid
• Sinónimos: (3R,5R)-7-[2-(4-Fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-yl-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid, (3R,5R)-7-[2-(4-Fluorophenyl)-3-Phenyl-4-(Phenylcarbamoyl)-5-Propan-2-Yl-Pyrrol-1-Yl]-3,5-Dihydroxy-Heptanoic Acid, (3R,5R)-7-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid, (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, (3S,5S)-7-[2-(4-Fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid, (3S,5S)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, (βR,δR)-2-(4-Fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, (βR,δR)-2-(p-Fluorophenyl)-β,δ-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid, 1H-Pyrrole-1-Heptanoic Acid, 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-, 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-rel-, 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, [R-(R*,R*)]-, 1H-pyrrole-1-heptanoate, 3-benzoyl-5-(4-fluorophenyl)-β,δ-dihydroxy-2-(1-methylethyl)-4-phenyl-, calcium salt, (betaR,deltaR)- (1:1), Atavastatin, Atofast, Atorcor, Atorfit 20, Atorin, Atoris, Atorvastatin Acid, Atorvox, Atrox, Cardyl, Lipilou, Lipinon, Statofilm, calcium bis{(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate}

Descripción

The drug is a calcium salt of (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid. It is an oral hypolipidemic agent that has been shown to reduce serum cholesterol levels and atherosclerotic lesion in humans. The mechanism of action of this drug is not fully understood but it may be due to its ability to reduce the expression of LDL receptors. This drug has been shown to inhibit the production of apoB in cultured cells and may also act by inhibiting the synthesis of cholesterol. It also inhibits cellular proliferation and reduces cellular proliferation in patients with chronic renal failure. The side effects are generally mild and include gastrointestinal disturbances, headache, dizziness, insomnia, rash, and muscle pain.

• Marca: Biosynth

Propiedades químicas

• Peso molecular: 558.64 g/mol
• Fórmula: C₃₃H₃₅FN₂O₅
• Pureza: Min. 98 Area-%
• Color/Forma: White Powder